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Treatment of locally advanced non-small cell lung cancer - 
neoadjuvant or adjuvant chemotherapy
Vokes, Everett E. 
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Over recent years combined modality therapy has become ﬁrmly es-
tablished as a standard in the treatment of patients with locoregionally 
advanced unresectable non-small cell lung cancer (NSCLC). In direct 
comparison, concomitant chemoradiotherapy was shown repeatedly 
to be superior to induction chemotherapy. A case can be made that 
concomitant chemoradiotherapy primarily addresses locoregional dis-
ease while induction chemotherapy might be better suited to eradicate 
distant micrometastatic foci. Therefore, continuing sequential and con-
comitant therapy might be beneﬁcial and the addition of induction or 
adjuvant chemotherapy to the concomitant chemoradiotherapy standard 
have been investigated. 
CALGB 39801 compared concomitant chemoradiotherapy using the 
carboplatin paclitaxel platform versus induction chemotherapy with 
carboplatin and paclitaxel for two cycles followed by identical chemo-
radiotherapy. While a numerical trend favored the induction chemo-
therapy arm, there was no signiﬁcant advantage for overall survival. 
Similarly, the Hoosier Oncology Group evaluated the administration of 
concomitant chemoradiotherapy using the cisplatin etoposide platform 
with or without three additional cycles of consolidation chemotherapy 
with docetaxel. This study was based on promising pilot data generated 
by the Southwest Oncology Group. Again, the study showed no signiﬁ-
cant survival advantage from the addition of concomitant chemoradio-
therapy. Therefore, at the present time, concomitant chemoradiotherapy 
should be regarded as the standard approach for most patients with 
unresectable non-small cell lung cancer. 
Induction chemotherapy may have a role for patients with poor perfor-
mance status who may not be candidates to undergo aggressive chemo-
radiotherapy. Certain targeted agents might be appropriate to investi-
gate in the consolidation setting under carefully deﬁned experimental 
conditions. This need is highlighted by the recent experience in SWOG 
0023 in which the administration of geﬁtinib as maintenance therapy 
was found to decrease survival rates. 
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The lung is an internal organ consisting of a complex branching system 
of airways leading to gas exchange units. Lung cancer consists of 
several cell types instead of a single cell type. Different cell types are 
preferentially located in different parts of the bronchial tree. There is no 
single method that can detect pre-invasive cancer in the entire bronchial 
epithelium and allow simultaneous tissue sampling for pathological 
diagnosis and molecular proﬁling. While computerized tomography, 
magnetic resonance imaging and ultrasound can detect objects in the 
sub-milliliter scale, photonic imaging can detect structural and func-
tional changes in cells and tissues down to the micron and sub-micron 
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range. It is therefore advantageous to use light to detect pre-invasive 
lung caner and preneoplastic lesions that are usually very thin and small.
When tissue is illuminated by light, the light can be absorbed, scattered, 
induce ﬂuorescence or vibration changes. Signiﬁcant differences in 
reﬂectance and autoﬂuorescence properties have been observed between 
normal, pre-malignant and malignant tissues. These differences in 
optical properties have been exploited to enhance the detection rate of 
high-grade bronchial dysplasia and carcinoma in-situ. Current commer-
cially available autoﬂuorescence bronchoscopy devices make use of a 
combination of autoﬂuorescence and reﬂectance. A blue or violet light is 
used to induce tissue autoﬂuorescence. The ﬂuorescence image is then 
combined with a blue, red and/or green reﬂectance image for display. 
In addition to multiple single center studies, there are 3 multi-center 
clinical trials and two randomized trials that showed improved detection 
rate with ﬂuorescence bronchoscopy or with ﬂuorescence-reﬂectance 
bronchoscopy compared to white-light bronchosocpy alone. Autoﬂuo-
rescence bronchoscopy has the advantage that a biopsy can be taken 
during the same examination for pathological conﬁrmation. For cancer 
beyond the range of the bronchoscope, gene expression analysis of 
bronchial brush cells holds promise to differentiate between malignant 
versus benign peripheral lung nodules. Autoﬂuorescence bronchoscopy 
has contributed to improved histopathological classiﬁcation and molecu-
lar proﬁling of preneoplastic lesions. It has become an integral part of a 
standard bronchoscopic examination for lung cancer diagnosis.
False-positive ﬂuorescence can occur due to inﬂammation or conditions 
that increase vascularity of the bronchial mucosa. Optical coherence 
tomography (OCT) can overcome this problem by allowing visualiza-
tion of the sup-epithelial layers. The principle of OCT is similar to ul-
trasound. Instead of using sound, infrared light is used. Back-scattered 
light from varying tissue depths can be used to delineate cellular and 
extra-cellular structures. Doppler OCT can add further information on 
vascular density and blood ﬂow. Recent studies showed that high-grade 
dysplasia, carcinoma in-situ and invasive cancer can be distinguished 
from normal, hyperplastic or metaplastic epithelium. Interruption of the 
basement membrane would indicate the presence of invasive cancer. 
Areas of inﬂammation also show distinctive changes. Since small pre-
neoplastic lesions can be removed by a biopsy procedure, OCT holds 
promise as a non-biopsy tool to study the natural history of preneoplas-
tic lesions and the effect of chemoprevention.
In the context of an early lung cancer detection program, approximately 
18% of cancers - majority of which being Stage 0 caners, are detected 
by ﬂuorescence bronchoscopy alone with a negative spiral CT. Lung 
cancer risk assessment models using biometric data such as family 
history, presence or absence of chronic obstructive pulmonary disease, 
family history of lung cancer and body mass index in addition to age, 
smoking history and occupational exposure are being validated. These 
models have the potential to predict the risk of lung cancer develop-
ment better than the Gail model for breast cancer. Prospective clinical 
trials need to be performed to validate the use of these lung cancer risk 
models to select individuals at highest risk of developing lung cancer 
for intensive screening utilizing both ﬂuorescence-reﬂectance bron-
choscopy and spiral CT to detect early cancer in both the central and 
peripheral airways that are amendable to curative therapies.
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Endobronchial ultrasound (EBUS) guided biopsy in respiratory disease 
is a promising new modality. The radial probe EBUS (20 MHz) has 
been used for the biopsy of peripheral lung lesions using the guide 
sheath. In addition, the radial probe EBUS guided TBNA has increased 
the yield of TBNA of mediastinal lymph nodes. However it is still not 
a real-time procedure with target visualization. To overcome these 
problems, a new convex probe endobronchial ultrasound (CP-EBUS, 
XBF- UC260F-OL8) with ability to perform real-time EBUS guided 
TBNA (EBUS-TBNA) was developed in collaboration with Olympus 
Optical Co. Tokyo, Japan 1, 2. This CP-EBUS is a ﬂexible bronchoscope 
with a linear curved array transducer on the tip with a frequency of 7.5 
MHz that scans parallel to the insertion direction of the bronchoscope. 
Images can be obtained by directly contacting the probe or by attaching 
a balloon on the tip and inﬂating with saline. The outer diameter of the 
insertion tube of the ﬂexible bronchoscope is 6.7 mm and that of the 
tip is 6.9 mm. A dedicated 22-gauge needle was developed to perform 
transbronchial aspiration. The needle can be visualized through the 
optics and on the ultrasound image. 
EBUS-TBNA was initially developed for lymph node staging of lung 
cancer. However from our experience, there are many other uses in 
clinical practice. The applications of EBUS-TBNA are (a) lymph node 
staging in lung cancer patients; (b) diagnosis of intrapulmonary tumors; 
(c) diagnosis of unknown hilar and/or mediastinal lymphadenopathy; 
and (d) diagnosis of mediastinal tumors. From our 5 year experience, 
we have not experienced any major complications. 
For lymph node assessment in lung cancer patients, EBUS-TBNA can 
be used for preoperative evaluation as well as post-chemotherapy and 
post-operative evaluation. To evaluate the usefulness of CP-EBUS 
in pre-operative lymph node staging of lung cancer, we performed 
EBUS-TBNA in 108 patients with lung cancer or suspected lung cancer 
having mediastinal lymph nodes suspected of malignancy. In 105 
patients, EBUS-TBNA was successfully performed to obtain samples 
from 163 lymph nodes. With respect to the correct prediction of lymph 
node stage, EBUS-TBNA had a sensitivity of 94.6%, speciﬁcity of 
100%, positive predictive value of 100%, negative predictive value of 
89.5%, and diagnostic accuracy rate of 96.3%. In the 20 suspected lung 
cancer cases, mediastinal lymph node was used for tissue diagnosis of 
malignancy as well as staging. As a result of EBUS-TBNA, 29 medias-
tinoscopies, 8 thoracotomies, 4 thoracoscopies, and 9 CT-guided PCNB 
were avoided 3. In addition, a cost effectiveness study comparing 
EBUS-TBNA to other conventional tools used for mediastinal staging 
